Homozygous plasminogen activator inhibitor-i (PAI-1 )-deficient (PAI-1 /-I) mice were generated by homologous recombination in D3 embryonic stem cells. Deletion of the genomic sequences encompassing the transcription initiation site and the entire coding regions of murine PAI-i was demonstrated by Southern blot analysis. A 3.0-kb PAI-i-specific mRNA was identified by Northern blot analysis in liver from PAI-1 wild type (PAI-i +1+) but not from PAI-1i--mice. Plasma PAI-i levels, measured 2-4 h after endotoxin (2.0 mg/kg) injection were 63±2 ng/ml, 30±10 ng/ml, and undetectable (< 2 ng/ ml) in PAl-i ++, heterozygous (PA-i +/-) and PAMl-/-mice, respectively (mean±SEM, n = 4-11). PAI-1-specific immunoreactivity was demonstrable in kidneys of PAI-1 +/+ but not of PAl-i--mice. SDS-gel electrophoresis of plasma incubated with '25I-labeled recombinant human tissue-type plasminogen activator revealed an 115,000-M, component with plasma from endotoxin-stimulated (0.5 mg/kg) PA-i +/+ but not from PAM--/-mice, which could be precipitated with a polyclonal anti-PAI-1 antiserum. PAM-i-mice were viable, produced similar sizes of litters as PA-+/+ mice, and showed no apparent macroscopic or microscopic histological abnormalities. (J. Clin. Invest. 1993. 92:2746-2755
Introduction
The fibrinolytic system has been claimed to play a role in a variety of biological phenomena ( 1, 2) . Activation of plasmin-tivator.
ogen by tissue-type plasminogen activator (t-PA)' is believed to be responsible not only for fibrin-specific clot lysis and maintenance of vascular patency (2) , but it is also believed to be involved in ovulation (3) (4) (5) , embryogenesis (6) , and brain function (7) . Plasmin generation by urokinase-type plasminogen activator (u-PA) is believed to play a role in a variety of tissue remodeling processes, such as embryo implantation and embryogenesis (3, 6, 8) , angiogenesis (3, 9) , inflammation (I ), cell invasion, and metastasis ( 10) .
Inhibition of the fibrinolytic system may occur at the level of plasmin, mainly by a2-antiplasmin or at the level of the plasminogen activators by specific plasminogen activator inhibitors (PAls) (11, 12) . Ofthose, endothelial or type 1 PAI (PAI-1 ) appears to be the primary physiological inhibitor of plasminogen activation ( i 1, 12) . It inactivates both t-PA and twochain u-PA by rapid formation of inactive 1:1 stoichiometric complexes. PAI-1 is synthesized in several tissues and its expression is highly regulated by various hormones and growth factors ( 12) .
Despite extensive biochemical characterization, the role of PAl-1 in vivo is poorly documented. The evidence for its presumed role in hemostasis, thrombosis, and thrombolysis is discussed in the accompanying paper ( 13 ) , but its role in other phenomena is less well documented. Several lines of evidence suggest that PAI-1 plays a role in gonadotropin-induced ovulation, healing of the ruptured follicle, and development of the corpus luteum (3, 4) . PAI-1 may also modulate embryo implantation via expression in the invasive trophoblast ( 14) and in the decidua (8) , where it may control excessive proteolysis. Serine protease inhibitors indeed suppress embryo implantation in rodents, supporting the implication of the fibrinolytic system in this phenomenon ( 15 ) .
To obtain new information on the role of PAI-1 in vivo, we have disrupted the PAI-1 gene in mice by homologous recombination in embryonic stem cells, whereby the entire coding region was deleted, and we have investigated its effects on organ development and reproduction. Methods Animals and blood collection. The mice were kept in microisolation cages on a 12-h day/ night cycle and were fed a regular chow. Unless otherwise stated, the mice were anesthetized by intraperitoneal injection of60 mg/ kg Nembutal (Abbott Laboratories, North Chicago, IL), and blood was collected by vena cava puncture with a 24-gauge needle.
Construction ofthe gene targeting vector. The PAI-1 gene was isolated from a BALB/c genomic library (Clontech Laboratories, Palo Alto, CA) (Prendergast, G., and M. Cole); 8.1 kb of total homology was included in the parental pNT-vector that contains a neomycin and a Herpes simplex virus thymidine kinase expression cassette ( 16) , as schematically represented in Fig. 1 . Initially, a 4.5-kb SalI-XhoI fragment from plasmid pX5.4, containing the 5'-flanking XbaI-XhoI genomic sequences, was ligated into the XhoI-site of the pNT vector to produce pNT.PAI5' (not shown). The XhoI-site is 1 ( 19) in embryonic stem cell medium (Dulbecco's modified Eagle's medium containing 4.5 g/liter glucose; Hazleton Laboratories, Lenexa, KS) and 15% heat-inactivated fetal bovine serum (Hyclone Laboratories, Salt Lake City, UT) supplemented with nonessential amino acids (GIBCO BRL, Gaithersburg, MD), 2 mM glutamine (GIBCO BRL), 0.1 mM fl-mercaptoethanol (Sigma Immunochemicals, St. Louis, MO), 100 U/ml penicillin/0.1 mg/ml streptomycin, and 1,000 U/ml recombinant leukemia inhibitory factor (Esgro; GIBCO BRL). The cells were grown on lethally irradiated (1,500 rad for 30 min) primary mouse embryonic fibroblasts, prepared from neomycin-resistant, f2m-deficient mice (provided by R. Jaenisch, Whitehead Institute, Cambridge, MA). Approximately 108 embryonic stem cells were electroporated with an electroporator from Bio-Rad Laboratories (Richmond, CA) (400 V, 25 ,uF, room temperature) with 100 j.g of NotI-linearized targeting vector in electroporation buffer (20 mM (22) .
To screen for embryonic stem cell colonies harboring a recombined PAI-1 gene, a SpeI-XbaI probe (Fig. 1, probe a) Recombinant PAI-I (rPAI-1) expression was induced by adding iso-
propylthio-fl-D-galactoside (1 mM final concentration). After 4 h, E.
coli cells were centrifuged for 15 min at 3,500 rpm and at 4°C, and the cell pellet was resuspended in 10 ml 25% sucrose, 15 mM Na-phosphate buffer, pH 6.0, to which the following reagents were added: 5 ml 0.25 M EDTA, 5,l aprotinin (750 U/ml), 5,l leupepsin (10 mg/ml), 260 Ml PMSF (10 mg/ml), 26 Ml DTT (10 mg/ml), 26 Ml pepstatin A (0.7 mg/ml), 26 Ml benzamidine/HCI (1 mM), 26 Ml antipain (10 mg/ml), and 8 ml of a solution containing 0.2% Nonidet P-40, 0.25 mM EDTA, and 50 mM Na-phosphate buffer, pH 6.0. After incubation for 10 min on ice, cells were sonicated on ice for 3 min with a sonifier (model no. 250, position no. 8; Branson Ultrasonics Corp., Danbury, CT), and the lysate was centrifuged at 20,000 rpm for 20 min at 40C. Recombinant murine PAI-I (rPAI-l ) from E. coli lysates was purified as described by Seetharam et al. (26) with minor modifications.
Briefly, the E. coli supernatant (-200 ml) was passed through a QSepharose column (2.5 X 10 cm) (Pharmacia, Uppsala, Sweden) equilibrated with 0.1 M NaCl, 0.05 M Na-phosphate buffer, pH 7.5, at a flow rate of25 ml/h. The rPAI-1 containing flow through from the Q-Sepharose column was adjusted to pH 6.0 and dialyzed against 0.1 M NaCl, 0.05 M Na-phosphate buffer, pH 6.0, before loading onto an SPSepharose column (2.5 X 12 cm) (Pharmacia) equilibrated with 0.1 M NaCl, 0.05 M Na-phosphate buffer, pH 6.0, at a flow rate of 30 ml/h. rPAI-I was eluted from the column using 0.05 M Na-phosphate buffer, pH 8.0. rPAI-l containing fractions were collected into 1 M acetate buffer, pH 4.5 (1/ 10 vol). Pooled fractions were adjusted to 0.3 M NaCl and to pH 5.5 and loaded onto a heparin-Sepharose column (0.9 x 15 cm) (Pharmacia) equilibrated with 0.3 M NaCl, 0.05 M acetate buffer, pH 5.5, at a flow rate of 10 ml/h. The bound rPAI-1 was then eluted using a NaCl gradient (0.3-1.1 M) in 0.05 M acetate buffer, pH 5.5. The purified material migrated as a single component with an apparent relative molecular mass of 45 kD on SDS-gels and reacted with anti-human PAI-I antibodies on Western blotting (data not shown). The purified rPAI-I was primarily obtained in the latent form, with a specific activity of 7,000 U/mg (representing -1% ofthe theoretical maximal specific activity calculated on the basis of a specific activity for t-PA of 500,000 U/mg and relative molecular mass of 70,000 and 45,000 for recombinant human t-PA (rt-PA) and rPAI-l, respectively). The rPAI-l could be reactivated by incubation with urea or guanidium hydrochloride according to the method of Hekman and Loskutoff (27) . After reactivation and extensive dialysis against cold phosphate-buffered saline (0.04 M phosphate, 0.14 M NaCl, pH 7.4), the reactivated rPAI-l had a specific activity of 180,000 U/mg.
Antibodies against purified rPAI-l were produced by immunization of rabbits. The IgG fraction, purified by chromatography on Protein A Sepharose (Pharmacia) recognized the 45-kD murine and the 50-kD human PAI-I on Western blotting (data not shown). Alternatively, murine monoclonal antibodies raised against human PAI-I were screened for their cross-reactivity with murine PAI-1. Out of 81 antibodies, 24 were found to exhibit significant cross-reactivity.
Histopathologic examination. Three PAI-I +1+ and three PAI-I mice of either sex, aged 7 mo, were killed with an overdose of Avertin (2,2,2-tribromoethanol; Aldrich Chemie, Bornem, Belgium) and perfusion-fixed with cold 10 mM Na-phosphate buffer, pH 7.4, followed by Bouin's fixative. Whole fixed mice were postfixed in Bouin's fixative until use. Representative sections of all tissues were selected for histopathological examination. The tissues included five cross sections of brain, two cross sections of spine with spinal cord, a section of knee with leg muscle, lung, heart, kidney, liver, intestinal tissues, stomach, reproductive organs, thyroid, adrenal, eye, and pancreas. Immunocytochemistry. Male and female mice were anesthetized with a mixture ofRompun (Bayer, Leverkusen, Germany) and Ketalar (Warner-Lambert, Zaventem, Belgium) and perfusion-fixed with cold (4°C) 0.01 M Na-phosphate buffer, pH 7.4, followed by 1% (wt/vol) paraformaldehyde in 0.1 M Na-phosphate buffer, pH 7.4. Tissues were dissected and immediately (without postfixation) submerged for 36 h in 0.1 M Na-phosphate buffer, pH 7.4, containing 20% (wt/vol) sucrose. Tissues were then frozen in liquid 2-methylbutane, and cryostat sections (15-25 Am) were produced at -26°C and were mounted on chromealum-gelatin-coated slides. Cryostat sections were soaked in 0.01 M Tris/HCl buffer, pH 7.6, containing 0.15 M NaCl and 0.1% (vol/vol) Triton X-100 (TBS-Triton) for 10 min, exposed to 20% normal goat serum (Department of Zoology, University of Leuven, Belgium) for 45 min, briefly rinsed in TBS-Triton, and exposed to varying concentrations of rabbit anti-PAI-1 antibodies obtained as described above, or of rabbit anti-human PAI-I antibodies (American Diagnostica Inc., Greenwich, CT). Optimal IgG concentrations for staining were found to be 1-2 ,g/ml when incubated at room temperature for 14 h. After incubation, the slides were treated with goat anti-rabbit IgGs (diluted 1:20 in TBS-Triton) for 30 min at room temperature, and then with rabbit peroxidase/antiperoxidase complexes (diluted 1:300 in TBS-Triton) for 30 min at room temperature. Peroxidase activity was revealed with 3,3'-diamino benzidine tetrahydrochloride (25 mg Active PAI-1 levels were also determined using a monoclonal antibody-based immunofunctional assay, specific for the PAI-1/rt-PA complex (29) . MA-16F1 1, a monoclonal antibody raised against human PAI-1, which cross-reacted for -30% with the recombinant murine PAI-I (rPAI-1 ) was used for capture, and a monoclonal antibody directed against rt-PA (MA-62E8), which did not (< 1%) cross-react with murine t-PA, was conjugated to horseradish peroxidase and used for tagging. Alternatively, MA 16F1 1 was replaced by polyclonal rabbit anti-PAI-I antibodies, yielding similar results (data not shown).
Immunoprecipitation of PAI-I in plasma samples was achieved by mixing 50 ,l plasma with 20 ,l CNBr-activated Sepharose beads, to which rabbit anti-rPAI-l was coupled ( 1.25 mg IgG/ml gel), for 2 h at room temperature, followed by removal ofthe beads by centrifugation. A rabbit antistaphylokinase antiserum coupled to Sepharose beads was used as a control antiserum.
Complexformation ofPAI-I with '25I-rt-PA. Incubation of plasma samples with '25I-rt-PA for generation oflabeled PAI/rt-PA complexes was carried out as previously described (30) . Briefly, plasma samples, obtained from mice injected 2 h previously with 0.5 mg/kg endotoxin were incubated with rt-PA, which was radiolabeled with '25I using the lodogen method. Active 125I-rt-PA was added in slight molar excess of active PAI-I (as determined by the method by Verheyen) to the 10-fold diluted plasma samples from PAI-I+/+ mice. An equal amount of '25I-rt-PA was added to the 10-fold diluted plasma from PAI-I-/-mice. After a 1 5-min incubation period at 37°C, the reaction was terminated by the addition of0.25 vol of 50mM Tris/HCl buffer, pH 8.0, containing 5 mM EDTA, 5% (wt/vol) SDS, 0.05% bromophenol blue, and heating for 30 s at 100°C. The mixtures were subjected to electrophoresis on a 10-15% gradient SDS-polyacrylamide gel. The relative position of the '251I-label was visualized by autoradiography. The autoradiograms were intentionally overexposed to obtain maximal sensitivity. Immunoprecipitation of PAI-l in plasma was carried out as described above in the section on PAI-I activity.
Statistical analysis. The statistical significance of differences between groups was determined using Student's t test for paired or unpaired values and two-sided P values.
Results

Targeting ofthe PAI-I gene
To target the murine PAI-I gene, a replacement-type targeting vector was constructed, in which a neomycin-expression cassette replaced the genomic sequences encompassing the entire coding regions of PAI-1, as schematically represented in Fig. 1 (Table I ). As shown in Table I , the enrichment obtained by double selection (G4 18 and FIAU) over the single selection (G418 only) ranged in two experiments between 4.9-fold and 6.0-fold. Genomic DNA from individual embryonic stem cell clones was digested with EcoRI and hybridized to probe a located adjacent to the 5' side of the homology region present in the targeting construct (Fig. 1) . Genomic DNA from wild type cells yielded a 8.5-kb fragment after EcoRI digestion, whereas the disrupted gene produced a 13.0-kb fragment (Fig. 2 A) .
After expansion of clonal populations of embryonic stem cells containing the disrupted allele, additional Southern blot analyses were performed on genomic DNA digested with SpeT (hybridized with probe a), PstI, and XmnI-BamHI (hybridized with probe c [ Fig. 1]) to confirm site-specific recombination at the PAI-I locus (data not shown). Finally, hybridization ofEcoRT-restricted genomic DNA with a neomycin-specific probe (Fig. 1, probe b) was used to reveal single integration of the targeting construct at the PAI-I locus (Fig. 2 B) , by exclusive generation of a 13.0-kb fragment from the targeted allele.
Germline transmission ofthe inactivated PAI-I gene Two independent clones that had undergone homologous recombination (clones P176 and P292) were then injected into C57BL/6J host blastocysts (Table IT) . With clone P292, the following chimeric animals were obtained: two males and one female with < 30% chimerism, one male and one female with 30-70% chimerism, and three males with > 90% chimerism. With clone P176, the corresponding numbers were: two males and one female with < 30% chimerism, three males and two females with 30-70% chimerism, three males and four females (Fig. 1) . WT, wild type; HR, homologously recombined.
with 70-90% chimerism, and twelve males and five females with > 90% chimerism. All these chimeras were tested for germline transmission of the mutated allele, which was obtained with three males obtained with clone P292 (P292-lA, P292-5B, and P292-5E), and one male and one female obtained with clone P176 (P176-12C and P176-13B). Thus, although a significant number of chimeric animals with > 90% coat color chimerism were obtained by injecting clone P176, only one male and one female chimera transmitted the mutation through the germline. Ofthe nongermline competent chimeras with > 90% chimerism, six males and two females were sterile, and two males and two females produced only one litter, despite continued breeding efforts for more than 8 mo.
To accelerate expansion ofthe PAI-1 transgenic colony, the initial heterozygous PAI--deficient (PAI-I+'-) F1 males were mated with several C57BL/6J wild type PAI-l (PAI-lI 'I) females to produce more PAI-1+"-male and female F2 offspring that had a genetic background of 25% of 129 and 75% of C57BL/6J. F3 PAI-l+'+ and homozygous PAI-l-deficient mice (PAI-l-/-) littermates with the 25% of 129: 75% of C57BL/6J genetic background were used throughout the present study.
Viability, fertily, and growth ofPAI-I deficient mice Heterozygous PAI-1 +/-mice (F2 generation) were intercrossed and their F3 offspring were genotyped 3 wk after birth by The individual ES cell clones were injected in the number of blastocysts indicated. Injected blastocysts were then transferred to pseudopregnant females and the number of live progeny and of chimeras determined. The number of chimeras transmitting the mutated allele through the germline is also indicated. 2750 Carmeliet et al. Southern blot analysis oftail tip DNA, digested with XmnI and BamHI or with PstI. A representative example ofsuch a Southern blot analysis of genomic DNA, restricted with XmnI and BamHI (Fig. 2 C) or with PstI (Fig. 2 D) from PAI-I+/+, PAI-+/l , and PAI--/-littermates is shown. Among the 623 F3 offspring tested, 164 were PAI-I+/+ (26.3%), 314 were PAI-l +/ (50.4%), and 145 were PAI--/-(23.3%) ( Table III A) . This distribution is not significantly different (chi-square test) from the expected 1:2:1 frequencies assuming equal viability ofPAI-1 +/+, PAI-I +/-, and PAI-l -/-mice. Also, PAI-l deficiency did not significantly alter the growth of young animals; at 4 wk of age, the weight of PAI-I -/-and PAI-1 +/+ mice were similar ( 15.7±0.4 g (n = 11 ) vs 16.4±0.5 g (n = 7), P= 0.31).
PAI-1-/-mice were intercrossed to document the effect of PAI-I gene disruption on reproduction. As shown in Table III B, F3 PAI-l/-mice produced similar sizes and numbers of litter (F4 generation) as F3 PAI-I +/+ mice. It appears, thus, that disruption of the PAI-1 gene did not significantly influence viability, fertility, or development.
A B neo 33±2 (25) 33±4 (15) Size and frequency of litters from F3 PAI-I'/+ and F3 PAI-lI-breeding pairs. The results represent mean±SEM of the number of data points indicated between brackets.
Histological examination
No significant histological abnormalities could be documented on microscopic examination ofthe tissues listed in the methods section. No signs ofbleeding were observed in any ofthe tissues in PAI-I-/-mice. The oldest PAI-1-/-mice presently available are 11 mo old and still appear healthy. RNA analysis Northern blot analysis ofRNA prepared from liver ofPAI-i+I+ and PAI-I / mice, pretreated 4 h earlier with 0.5 mg/kg endotoxin, hybridized with a PAI-l-specific cDNA probe, revealed the specific 3.0-kb mRNA in PAI-I+'+ mice, while no such mRNA could be detected in the PAI-I / mice (Fig. 3 A) .
Rehybridization of the same blot with the neomycin-specific probe revealed the presence of a 1.3-kb neomycin mRNA in the PAI-I/-, but not in the PAI-I+'+ mice (Fig. 3 B) .
Immunocytochemical analysis ofPAI-I
Cryostat sections of the kidneys of PAI-l+/+ and PAI-l /-mice were stained with a polyclonal rabbit anti-PAI-l antiserum, which recognized purified rPAI-1 on a Western blot (data not shown). Very weak PAI-I immunoreactivity was ob- Figure 3 . Northern blot analysis of RNA from liver after endotoxin stimulation of the mice. 20 ,g of total RNA, prepared from liver was analyzed by Northern blot analysis using a PAI-l-specific probe (A) or a neomycin-specific probe (neo) (B). In PAI-I +1+ mice, a 3.0-kb PAl-I-specific mRNA is present, which is not detectable in PAI-iI l mice. Conversely, served in structures, tentatively identified as the juxtaglomerular apparatus in the kidneys of PAI-I+'+, but not of PAI-I --mice (Fig. 4 A; only PAI-I mice are shown). Intraperitoneal injection of endotoxin (2 mg/kg) 4 h before killing the animals revealed substantial induction of PAI-I immunoreactivity in the glomeruli of PAI-I+1+ mice (Fig. 4 B) , but not of PAI-I1 -littermates (Fig. 4 C) (five animals checked), even when the antiserum was used at a 500-fold higher concentration of anti-PAI-I IgGs (200 gsg/ml) than required to obtain a positive signal in the PAI-iI + mice (0.4 Ag/ml). Preadsorp-tion of the antiserum with recombinant human PAI-I eliminated positive staining in the wild type mice (Fig. 4 D) . Similar data were obtained using a cross-reacting rabbit anti-human PAI-I antiserum (data not shown).
PAI activity assays Amidolytic assay. Similar background PAI activities were obtained in plasma from PAI-i +/+, PAI-+/-, and PAI--/-mice (Table IV A ). 4-6 h after endotoxin injection (2.0 mg/ kg), PAI activity was however significantly increased in PAI-I+/+ and PAI-+/-mice, but not in PAI-T-/-mice.
To check whether the observed PAI activity was related to PAI-I and not to other protease inhibitors, plasma samples of PAI-i +/+ and PAI-T-/-mice were preabsorbed with a PAT-I-specific and with an irrelevant antiserum. Absorption with the PAI-1-specific antiserum, but not with the irrelevant antiserum, of plasma from endotoxin-treated PAI-I+/+ mice reduced the PAI activity to the levels observed in plasma from untreated PAI-I +/+ mice. Importantly, the PAI-activity levels in plasma from endotoxin-treated or untreated PAI--/-mice were not reduced after preadsorption with the PAI-l-specific antiserum. These findings suggest that the PAI activity induced with endotoxin in PAI-i +/+ is related to PAI-1, and that the similar "baseline" activity observed in PAI-+/'+, PAI-+/-, and PAI--/-mice is not related to PAI-1.
Immunofunctional assay. The immunofunctional assay for active PAI-I levels described in Methods was developed to improve the specificity of the PAI assays for PAI-1. Baseline PAI levels were undetectable (< 2 ng/ml) in plasma from PAI-+'/+, PAI-I +/-, and PAI-I -/-mice. 4-6 h after injection of2 mg/kg ofendotoxin, an increase ofthe PAI-I plasma levels over background was only observed in PAI-I +/+ and PAI-I +/-mice (Table IV B). Preadsorption of plasma from endotoxin-treated PAI-I +/+ mice with PAI-1-specific IgGs, but not with irrelevant IgGs, reversed the increased antigen levels to baseline.
Traces of reactivated rPAT-1 added to PAI-I -I-plasma were quantitatively recovered, indicating that the absence ofdetectable active PAT-I in plasma of PAI-I --mice was not caused by a higher degree of PAI-I inactivation (data not shown).
'25I-rt-PA: PAI-I complexformation The reactivity ofPAI in plasma ofendotoxin-treated mice with rt-PA was analyzed by SDS-gel electrophoresis using '25T-labeled rt-PA. Autoradiograms were overexposed to visualize the formation of trace amounts of complexes in the plasma from PAI-I -I-mice. When '25T-rt-PA was added to plasma ofendotoxin-treated PAI-i+I+ mice (Fig. 5 A, lanes 1-3) , a 1251-labeled complex with a similar apparent molecular weight as that obtained with mixtures of reactivated rPAT-1 and '25T-rt-PA (Fig. 5 A, lane 5) was observed. The formation ofthis complex was markedly reduced when plasma from endotoxin-treated PAI-I ++ mice was adsorbed with a specific PAI-I (Fig. 5 B,  lane 1) but not with a control serum (Fig. 5 B, lane 3) . In plasma from endotoxin-treated PAI-I1--mice, two very faint '25T-labeled complexes with closely related relative molecular weights were observed after incubation with '25T-rt-PA (Fig. 5  A, lane 4) . Formation of these complexes could, however, not be prevented by preadsorbing the plasma with either the PAIi-specific (Fig. 5 B, lane 2) or the control serum (Fig. 5 B, lane   4) , suggesting that these compounds may represent complexes of '25I-rt-PA with other protease inhibitors. Plasma of endotoxin treated PAI-i --mice did not prevent the formation of the complex between '25I-rt-PA and reactivated rPAT-1 added to the plasma (Fig. 5 B, lane 5) .
Discussion
Despite extensive characterization of the biochemical and molecular properties ofPAI-1, much ofour knowledge about its in vivo role is deduced from correlation between elevated PAl-i levels and a variety of pathological disorders.
To investigate the effect of PAI-I gene disruption on organ development and reproduction, as well as on hemostasis, thrombosis, and thrombolysis, PAI-1-deficient mice were generated by homologous recombination in embryonic stem cells. Inactivation of the PAI-l gene was demonstrated by Southern blot analysis, and confirmed by the absence of detectable PAI-1-specific mRNA, PAI-I -related antigen, and functional protein. The present study describes the generation of the PAI-lI"-mice and the consequences of PAI-1 gene disruption on organ development and reproduction. In an accompanying paper ( 13) , the biological effects of PAI-l gene disruption on hemostasis, thrombosis, and thrombolysis are described.
The most surprising finding of the present study was that PAI-I -deficient mice are viable, fertile, and without significant abnormalities in organogenesis and development. Although patients with low or absent PAI-l levels have previously been described (reviewed in reference 13), it remained unknown whether PAI-1-deficient females can ovulate and support normal embryonic growth. Maternal expression of PAI-l in the decidual cells is indeed believed to control invasion ofthe u-PA expressing trophoblasts ( 3, 8) , whereas PAI-I expression in the maternal ovarian cells around the time ofovulation, is thought to control follicular rupture (4) and remodeling ofthe postovulatory ovary (4) . The present findings, however, demonstrate that reproduction and development proceed normally, also in the absence of PAI-1. Possibly, other protease inhibitors, such as PAI-2, a2-antiplasmin, a2-macroglobulin, C,-esterase inhibitor, or ax-antitrypsin, which are known to reduce plasminogen activation and/or plasmin activity, might compensate for PAI-1 deficiency. In view of the potential hazards of uncontrolled plasminogen activation for bleeding and tissue destruction, functional redundancy of protease inhibitors might indeed be advantageous. Another plausible explanation for the lack of major abnormalities in reproduction and development is, however, that PAI-l deficiency in mice induces only a mild hyperfibrinolytic state, as detailed in the accompanying paper ( 13 ) .
Although we did not use isogenic targeting DNA, which improves the frequency of gene targeting ( 31 ) , an acceptable targeting frequency (5%; 17 out of340 double-resistant ES colonies) was obtained. This may have been caused by the incorporation of a fairly large amount of homologous DNA sequence ( -8 kb) into the targeting construct. In addition, three homologously recombined ES cell colonies were obtained, which also comprised one or more randomly integrated copies of the targeting construct (data not shown), and which were, therefore, discarded. It is not obvious why a number of chimeras with > 90% coat color chimerism did not transmit the inactivated PAI-1 gene. Possibly, poor germ cell chimerism despite significant coat color chimerism ( 19, 20) and/or sex conversion of female host embryo's by male ES cells (32) may explain the observed sterility.
It is interesting to note that disruption ofthe PAI-l gene did not provoke any "spontaneous" apparent functional or histological abnormalities. It should be noted, however, that PAI-1 gene expression is highly regulated by a variety of growth factors, hormones, and cytokines involved in inflammation and tissue remodeling ( 12) . Thus, the biological consequences of PAI-1 gene disruption might be more apparent after chronic stimulation of PAI-1 gene expression.
In conclusion, disruption of the PAI-l gene is compatible with normal viability, development and fertility. Its consequences on the development of disease states with a disturbed coagulation/fibrinolytic balance, such as atherosclerosis, glomerulonephritis, and malignancy, need to be further explored.
